Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, March 2011

Altmetric Badge

Citations

dimensions_citation: 36 Dimensions

Readers on

mendeley: 79 Mendeley

Summary Dimensions citations

So far, Dimensions has found 36 publications that cite this research output.

36

The most recent citing publications are shown below. View all 36 publications that cite this research output on Dimensions.

Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors

Article in Advances in Therapy (April 2024)

Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany

Article in PharmacoEconomics - Open (March 2024)

Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe

Article in Journal of Medical Economics (September 2022)